Alpine Immune Sciences, Inc. ALPN
At closeMay 17, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 4.46B
- Revenue (ttm)
- 56.52M
- Profit margin
- -65.17%
- Shares out
- 68.60M
- Forward P/E
- -32.48
- Volume
- 4.29M
- Open
- 64.98
- Previous close
- 64.97
- Day's range
- 64.97 – 65.00
- Beta
- 0.97
- Analysts
- Buy
- Price target
- 62.00 (-4.6%)
- Earnings date
- May 9, 2024
Key statistics
- Enterprise value
- 4.16B
- PEG ratio
- 0.00
- Price / sales
- 78.85
- Price / book
- 12.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -25.10%
- Free cash flow
- -41.41M
- Total cash
- 305.66M
- Total debt
- 9.65M
- Return on equity
- -14.67%
- Short % of float
- 8.27%
- 50-day average
- 53.15
- 200-day average
- 26.84
Analyst view
Consensus: buy
- Target (low)
- 44.00
- Target (mean)
- 62.00
- Target (high)
- 65.00
- Strong buy2
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -0.42.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| Mar 18, 2024 | Dec 1, 2023 | -0.32 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.35 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.38 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.37 | — | — | — |
| Mar 23, 2023 | Dec 1, 2022 | -0.27 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2023 | Berenberg | init | — | Buy |
| Oct 4, 2023 | RBC Capital | init | — | Outperform |
| Sep 12, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 10, 2023 | Oppenheimer | main | Outperform | Outperform |
| Aug 31, 2023 | Wedbush | reit | Outperform | Outperform |
| Aug 30, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alpineimmunesciences.com
News
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline 
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN 
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN 
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? 
Could This Stock Be the Next Biotech Buyout? 
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN 
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex 
2 Biotech Stocks Driving the Nasdaq Today 
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
Your note
Sign in to keep a note on ALPN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CUI XIANGMIN | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 17, 2024 | 0 |
| DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 17, 2024 | 6,582,380 |
| DURAND REMY | Officer | Conversion of Exercise of derivative security | May 7, 2024 | 133,392 |
| FUHS ULRICH MARTIN | Officer | Conversion of Exercise of derivative security | May 7, 2024 | 30,120 |
| GOLD MITCHELL H | Chief Executive Officer | Conversion of Exercise of derivative security | May 7, 2024 | 2,736,400 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Conversion of Exercise of derivative security | Jan 10, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 13.63% | 6,708,288 | 68.96M | Jun 29, 2023 |
| RA Capital Management, L.P. | 9.53% | 4,691,178 | 48.23M | Jun 29, 2023 |
| Orbimed Advisors LLC. | 8.30% | 4,081,592 | 41.96M | Jun 29, 2023 |
| Great Point Partners LLC | 6.84% | 3,363,688 | 34.58M | Jun 29, 2023 |
| Frazier Life Sciences Management, L.P. | 6.07% | 2,985,757 | 30.69M | Jun 29, 2023 |
| Lynx1 Capital Management Lp | 5.43% | 2,670,472 | 27.45M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.73% | 851,829 | 8.76M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 1.49% | 730,661 | 9.02M | Aug 30, 2023 |
| Fidelity Advisor Biotechnology Fund | 0.80% | 394,000 | 4.94M | Jul 30, 2023 |
| Vanguard Extended Market Index Fund | 0.70% | 345,108 | 3.55M | Jun 29, 2023 |
| Fidelity Small Cap Index Fund | 0.58% | 287,037 | 3.60M | Jul 30, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.42% | 206,049 | 2.54M | Aug 30, 2023 |